Role of gut microbiome in autism spectrum disorder and its therapeutic regulation

MA Taniya, HJ Chung, A Al Mamun, S Alam… - Frontiers in Cellular …, 2022 - frontiersin.org
Autism spectrum disorder (ASD) is a neurological disorder that affects normal brain
development. The recent finding of the microbiota–gut–brain axis indicates the bidirectional …

Current concepts and treatments of schizophrenia

P Stępnicki, M Kondej, AA Kaczor - Molecules, 2018 - mdpi.com
Schizophrenia is a debilitating mental illness which involves three groups of symptoms, ie,
positive, negative and cognitive, and has major public health implications. According to …

International Union of Basic and Clinical Pharmacology. CX. Classification of receptors for 5-hydroxytryptamine; pharmacology and function

NM Barnes, GP Ahern, C Becamel, J Bockaert… - Pharmacological …, 2021 - ASPET
5-HT receptors expressed throughout the human body are targets for established
therapeutics and various drugs in development. Their diversity of structure and function …

The physiology, signaling, and pharmacology of dopamine receptors

JM Beaulieu, RR Gainetdinov - Pharmacological reviews, 2011 - ASPET
G protein-coupled dopamine receptors (D1, D2, D3, D4, and D5) mediate all of the
physiological functions of the catecholaminergic neurotransmitter dopamine, ranging from …

Dopamine targeting drugs for the treatment of schizophrenia: past, present and future

P Li, G L. Snyder, K E. Vanover - Current topics in medicinal …, 2016 - benthamdirect.com
Schizophrenia is a chronic and debilitating neuropsychiatric disorder affecting
approximately 1% of the world's population. This disease is associated with considerable …

Signalling bias in new drug discovery: detection, quantification and therapeutic impact

T Kenakin, A Christopoulos - Nature reviews Drug discovery, 2013 - nature.com
Agonists of seven-transmembrane receptors, also known as G protein-coupled receptors
(GPCRs), do not uniformly activate all cellular signalling pathways linked to a given seven …

[PDF][PDF] Treatment of patients with schizophrenia

AF Lehman, LB Dixon, TH McGlashan… - American Psychiatric …, 2010 - umh1946.umh.es
Originally published in February 2004. This guideline is more than 5 years old and has not
yet been updated to ensure that it reflects current knowledge and practice. In accordance …

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

S Miyamoto, N Miyake, LF Jarskog… - Molecular …, 2012 - nature.com
Since the introduction of chlorpromazine and throughout the development of the new-
generation antipsychotic drugs (APDs) beginning with clozapine, the D 2 receptor has been …

[HTML][HTML] 5-HT2C receptor structures reveal the structural basis of GPCR polypharmacology

Y Peng, JD McCorvy, K Harpsøe, K Lansu, S Yuan… - Cell, 2018 - cell.com
Drugs frequently require interactions with multiple targets—via a process known as
polypharmacology—to achieve their therapeutic actions. Currently, drugs targeting several …

Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II

SF Zhou - Clinical pharmacokinetics, 2009 - Springer
Part I of this article discussed the potential functional importance of genetic mutations and
alleles of the human cytochrome P450 2D6 (CYP2D6) gene. The impact of CYP2D6 …